Advanced Therapeutics最新文献_第4页

Issue Information (Adv. Therap. 3/2025) 发布信息（Adv. Therap. 3/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-19 DOI: 10.1002/adtp.202570007

引用次数: 0

Nanoparticles in Allergen-Delivery Systems for Allergen-Specific Immunotherapy (Adv. Therap. 3/2025) 纳米颗粒用于过敏原特异性免疫治疗的过敏原递送系统（Adv. Therap. 3/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-19 DOI: 10.1002/adtp.202570008

Jiann Huey Lee, Rona Chandrawati, N. Alice Lee

引用次数: 0

Therapeutic Potential of Inulin-Coated MCT Microcapsules in Modulating the Gut Microbiome for Effective Treatment of Diet-Induced Obesity (Adv. Therap. 3/2025) 菊粉包被的MCT微胶囊调节肠道微生物群有效治疗饮食性肥胖的治疗潜力（Adv. Therap. 3/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-19 DOI: 10.1002/adtp.202570006

Amin Ariaee, Hannah R. Wardill, Anthony Wignall, Aurelia S. Elz, Leah Wright, Clive Prestidge, Paul Joyce

引用次数: 0

Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance 抗生素-多阳离子肽偶联是克服达托霉素耐药的有效策略

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-18 DOI: 10.1002/adtp.202400473

Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl

{"title":"Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance","authors":"Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl","doi":"10.1002/adtp.202400473","DOIUrl":"https://doi.org/10.1002/adtp.202400473","url":null,"abstract":"The benefit that antibiotics confer to the welfare of mankind is threatened by bacterial resistance. Resistance to daptomycin, a cyclic lipopeptide frequently used for the treatment of complicated bacteremia, is a prime example of this alarming situation. As the restricted number of antibacterial drug targets limits de novo development, chemical modification of existing compounds represents an alternative development option for future antimicrobials. This approach involves altering compounds to target bacteria through multiple mechanisms and/or to reinforce them against resistant strains. Herein, the conjugation of polycationic peptides to daptomycin enhances its effectiveness against a highly daptomycin-resistant laboratory strain of Staphylococcus aureus and clinical isolates of Enterococcus faecium with reduced daptomycin sensitivity. Notably, unlike daptomycin, the activity of these conjugates does not necessarily depend on the calcium concentration. In addition to regaining bacteriolytic activity, the findings indicate the acquisition of an additional or amended mode of action as evidenced by pore formation and the disruption of membrane potential. The combination of enhanced in vitro potency, in vivo activity, and tolerability highlights the potential of this drug modification strategy in combating multidrug-resistant bacteria.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

On the Relentless Pursuit of an Oral Insulin Delivery System: How Far is Too Far? 对口服胰岛素输送系统的不懈追求：到底有多远？

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-16 DOI: 10.1002/adtp.202400566

Sourav Bhattacharjee

{"title":"On the Relentless Pursuit of an Oral Insulin Delivery System: How Far is Too Far?","authors":"Sourav Bhattacharjee","doi":"10.1002/adtp.202400566","DOIUrl":"https://doi.org/10.1002/adtp.202400566","url":null,"abstract":"As the scientific community celebrates the centenary year of insulin discovery, developing oral insulin delivery systems remains challenging, with disappointing progress. On the contrary, injectable formulations, despite initial setbacks due to poor patient compliance and issues with painful daily injections, have improved considerably—and currently remain the mainstay of insulin therapeutics. Advanced microneedle technology has enabled insulin delivery with minimal nociception in conjunction with automated, user-friendly delivery platforms. Furthermore, integrating modalities like insulin pumps delivering precise doses based on blood glucose monitoring has emerged. Conversely, oral insulin delivery continues to face arcane challenges, including the denaturation of insulin due to acidic gastric juice, a hostile gut mucus barrier that immobilizes and then removes particulate formulations, and a portal circulation that shunts the residue minuscule (nano)particulate dose from the bloodstream into the liver followed by macrophage activation and hepatobiliary elimination. Unless these barriers are negotiated, breaking the impasse in oral insulin delivery remains elusive. This perspective argues in favor of focusing solely on injectable insulin while deprioritizing, if not fully ceasing, further research toward developing oral insulin formulations to prevent wasting both taxpayers’ money and unethical consumption of animal lives.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400566","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydrogel Delivering All-Trans Retinoic Acid to Regulate Macrophage Polarization to Enhance Chemo-Immunotherapy for Gastric Cancer

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-12 DOI: 10.1002/adtp.202400024

Ruobing Bai, Gang Wang, Boru Hou, Dengfeng Wang, Ruihao Li, Zipeng Xu, Weibin Ma, Hongbin Liu

{"title":"Hydrogel Delivering All-Trans Retinoic Acid to Regulate Macrophage Polarization to Enhance Chemo-Immunotherapy for Gastric Cancer","authors":"Ruobing Bai, Gang Wang, Boru Hou, Dengfeng Wang, Ruihao Li, Zipeng Xu, Weibin Ma, Hongbin Liu","doi":"10.1002/adtp.202400024","DOIUrl":"https://doi.org/10.1002/adtp.202400024","url":null,"abstract":"As Gastric cancer is one of the most common gastrointestinal malignancies in China, with a 5-year relative survival rate of ≈40%. Therefore, the development of new strategies to treat gastric cancer becomes urgent. In recent years, an increasing number of studies have found that all-trans retinoic acid (Tre) can induce the polarization of M2 macrophages toward M1 in the tumor immune microenvironment (TIME), and therefore play a due role in this cancer treatment. This research proposes to load doxorubicin (DOX) and Tre in mesoporous silica, which is then loaded into sodium alginate slow-release Gel to obtain the final product (GEL-MSDT). Gel-MSDT sustained-release hydrogel can release DOX and Tre locally in tumor, kill tumor cells, induce tumor immunogenic death, regulate tumor-associated macrophage phenotype, and promote anti-tumor immune response. Gel-MSDT hydrogel can coordinate chemotherapy with immunotherapy, and delay release locally to play a lasting anti-tumor immune effect. The results of in vitro and in vivo experiments show that hydrogel can significantly inhibit tumor growth, providing an effective new strategy for the treatment of gastric cancer.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative Network Pharmacology and Bulk RNA-Seq Unveil Berberine's Modulation of Mitochondrial Function and Oxidative Stress via SOD2 in Experimental Models of Ovarian Cancer

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-12 DOI: 10.1002/adtp.202400417

Yujie Cheng, Bing Xiong, Jing Guo, Xiao Li, Lingwei Li, Jiajun Wang, Jiale Li, Siqi Liu, Hang Zhou, Lian Wang, Zhongping Cheng

引用次数: 0

Malaria Chemotherapeutics What Next for Africa 疟疾化疗：非洲的下一步是什么

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-05 DOI: 10.1002/adtp.202400453

Lucy Ochola, Jesse Gitaka, Bernard Kanoi, Clare Njoki Kimani, Hoseah M. Akala, Martin Omondi Alfred, Lynette Isabella Ochola-Oyier, Bernhards Ogutu

{"title":"Malaria Chemotherapeutics What Next for Africa","authors":"Lucy Ochola, Jesse Gitaka, Bernard Kanoi, Clare Njoki Kimani, Hoseah M. Akala, Martin Omondi Alfred, Lynette Isabella Ochola-Oyier, Bernhards Ogutu","doi":"10.1002/adtp.202400453","DOIUrl":"https://doi.org/10.1002/adtp.202400453","url":null,"abstract":"Malaria remains a significant health challenge in sub-Saharan Africa, accounting for 90% of the global burden of disease. Recent studies have reported an increase in the number of malaria cases and a decrease in deaths. However, these gains can be reversed by emerging resistance to artemisinin and changing climatic conditions. Over the past 30 years, Africa has adopted artemisinin combination therapy (ACT) to treat uncomplicated malaria. Increasingly, reports of parasitic mutations conferring tolerance to artemisinin have emerged in several countries, particularly in East Africa. Although markers of resistance to various partner drugs are known, the potential failure of artemisinin can rapidly alter the situation, especially as the Kelch 13 gene, which confers resistance to artemisinin, becomes less conserved. It is anticipated that there will be a need to switch from current ACTs to new combinations or create a framework for multiple first-line deployment. However, this poses challenges ranging from timely review of policies, training of healthcare workers, access, and deployment to the most peripheral health facilities in remote areas. This review outlines several critical factors that can potentially influence decision making in this new paradigm shift, including insufficient funding and challenges in the development of pharmaceutical products.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoconjugate Improves Cognitive Deficit and Limits the Pathogenic Tau Burden in Okadaic-Acid-Induced Alzheimer's Mice 纳米缀合物改善冈田酸诱导的阿尔茨海默病小鼠的认知缺陷并限制致病性Tau负担

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-03 DOI: 10.1002/adtp.202400462

Qiuju Liang, Shoubo Xiang, Pengzhen Wang, Lian Chen, Hongyi Cao, Cheng Tian, Tingting Jiang, Hua Zuo, Zhen Tian, Sanjib Bhattacharyya

{"title":"Nanoconjugate Improves Cognitive Deficit and Limits the Pathogenic Tau Burden in Okadaic-Acid-Induced Alzheimer's Mice","authors":"Qiuju Liang, Shoubo Xiang, Pengzhen Wang, Lian Chen, Hongyi Cao, Cheng Tian, Tingting Jiang, Hua Zuo, Zhen Tian, Sanjib Bhattacharyya","doi":"10.1002/adtp.202400462","DOIUrl":"https://doi.org/10.1002/adtp.202400462","url":null,"abstract":"Alzheimer's disease (AD) is characterized by a progressive loss of cognition and its distinct hyperphosphorylated Tau (p-tau) pathology. Both insulin resistance(IRT) and p-tau share a causal relationship in AD, whereas the connective mechanism between them remains largely unknown. Tau protein is considered the primary target to combat AD as loss of Tau function triggers neuronal loss in AD. In the prior report, it is observed that self-therapeutic gold nanoparticles alleviate Tauopathy in models of AD. Gold nanoparticles (AuNPs)─polyethylene glycol 2000 (PEG2000)─transferrin (Tf) nanoconjugate is synthesized for passive targeting to pharmacologically regulate neuronal tau. It is observed that AuNPs─PEG2000─Tf decreases p-tau while restores insulin receptor(IR) and activates protein kinase B (AKT) kinase in SHSY5Y cell overexpressing Tau. AuNPs─PEG2000─Tf downregulates transferrin receptor by inhibiting recombinant divalent metal transporter 1 protein, affecting Fe2+ accumulation. AuNPs─PEG2000─Tf improves learning ability of mice in okadaic-acid-induced, stereotaxic model in a dose-dependent fashion compared to memantine and subsequently decreases both p-tau and acetyl tau levels and upregulates the AKT signal. Changes in p-tau/Tau index from mouse brain homogenate is diminished following AuNPs─PEG2000─Tf treatment as a desired therapeutic outcome. Given AuNPs─PEG2000─Tf treatment restricts pathogenic conversion of Tau (p-tau, acetyl Tau), further investigation is warranted to bridge the connection between gold-nanoparticle-mediated alteration of IRT and AD progression.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanotechnology in Gene Editing: Pioneering CRISPR-Cas Delivery Systems to Tackle Antibiotic Resistance 纳米技术在基因编辑：开拓CRISPR-Cas传递系统，以解决抗生素耐药性

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-03 DOI: 10.1002/adtp.202400412

Sahar Gholamian, Pooya Baghaee, Mohammad Doroudian

{"title":"Nanotechnology in Gene Editing: Pioneering CRISPR-Cas Delivery Systems to Tackle Antibiotic Resistance","authors":"Sahar Gholamian, Pooya Baghaee, Mohammad Doroudian","doi":"10.1002/adtp.202400412","DOIUrl":"https://doi.org/10.1002/adtp.202400412","url":null,"abstract":"The rise of antibiotic-resistant bacteria, driven by antibiotic misuse, is a major global health threat. Addressing this issue requires understanding resistance mechanisms and developing innovative solutions. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated systems (Cas), a genome-editing tool derived from prokaryotic defense mechanisms, offers precise targeting of antibiotic-resistant genes. By reprogramming CRISPR-Cas, bacteria can be killed or resensitized to antibiotics through plasmid curing. However, clinical applications face challenges, particularly in delivering CRISPR-Cas components effectively. Nanotechnology has emerged as a promising approach for targeted delivery to tissues and cells. This paper explores the molecular mechanisms of antibiotic resistance, emphasizing the structure and function of CRISPR-Cas systems and their delivery mechanisms. It highlights the use of nanoparticles (NPs) and nanoscale carriers to deliver CRISPR-Cas components, reviewing recent studies that combine NPs and CRISPR to target resistance genes. Additionally, the paper discusses current challenges and future prospects in this field, underscoring the potential of CRISPR-Cas and nanotechnology to combat antibiotic resistance.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0